Suyeon Kim, Ki Wook Lee, Yongjin Yoo, Sang Hee Park, Ji Won Lee, Suhyun Jeon, Shaginyan Illia, Pooja Joshi, Hyun Woo Park, Han-En Lo, Jimin Seo, Yeonwoo Kim, Min Chang, Tae Jin Lee, Jong Bae Seo, Sung-Hak Kim, Carlo M Croce, Inki Kim, Sung-Suk Suh, Young-Jun Jeon
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has chemotherapeutic potential as a regulator of an extrinsic apoptotic ligand, but its effect as a drug is limited by innate and acquired resistance. Recent findings suggest that an intermediate drug tolerance could mediate acquired resistance, which has made the main obstacle for limited utility of TRAIL as an anti-cancer therapeutics. We propose miRNA-dependent epigenetic modification drives the drug tolerant state in TRAIL-induced drug tolerant (TDT)...
2024: Animal Cells and Systems